Merck & Co., Inc. Stock Forecast, Price & News

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Merck & Co., Inc. in the last twelve months. There are currently 3 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Merck & Co., Inc. stock.
View analyst ratings for Merck & Co., Inc. or view top-rated stocks.

Wall Street analysts have given Merck & Co., Inc. a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Merck & Co., Inc. wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Merck & Co., Inc. saw a increase in short interest in the month of August. As of August 13th, there was short interest totaling 26,690,000 shares, an increase of 15.2% from the July 29th total of 23,170,000 shares. Based on an average daily trading volume, of 10,740,000 shares, the short-interest ratio is currently 2.5 days.
View Merck & Co., Inc.'s Short Interest.

Merck & Co., Inc. is scheduled to release its next quarterly earnings announcement on Thursday, October 28th 2021.
View our earnings forecast for Merck & Co., Inc..

Merck & Co., Inc. will be holding an earnings conference call on Thursday, October 28th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

Merck & Co., Inc. (NYSE:MRK) released its quarterly earnings data on Wednesday, July, 28th. The company reported $1.31 earnings per share (EPS) for the quarter, hitting the Thomson Reuters' consensus estimate of $1.31. The company had revenue of $11.40 billion for the quarter, compared to analyst estimates of $11.21 billion. Merck & Co., Inc. had a trailing twelve-month return on equity of 50.93% and a net margin of 11.48%. During the same period in the prior year, the business earned $1.37 earnings per share.
View Merck & Co., Inc.'s earnings history.

Merck & Co., Inc.'s stock was trading at $79.25 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, MRK shares have decreased by 9.4% and is now trading at $71.81.
View which stocks have been most impacted by COVID-19.

Merck & Co., Inc. declared a quarterly dividend on Tuesday, July 27th. Stockholders of record on Wednesday, September 15th will be paid a dividend of $0.65 per share on Thursday, October 7th. This represents a $2.60 dividend on an annualized basis and a yield of 3.62%. The ex-dividend date is Tuesday, September 14th.
View Merck & Co., Inc.'s dividend history.

Merck & Co., Inc. pays an annual dividend of $2.60 per share and currently has a dividend yield of 3.61%. The dividend payout ratio of Merck & Co., Inc. is 43.77%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Merck & Co., Inc. will have a dividend payout ratio of 41.40% next year. This indicates that Merck & Co., Inc. will be able to sustain or increase its dividend.
View Merck & Co., Inc.'s dividend history.

Merck & Co., Inc. issued an update on its FY 2021 earnings guidance on Thursday, August, 5th. The company provided earnings per share (EPS) guidance of $5.470-$5.570 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $6.150. The company issued revenue guidance of $46.40 billion-$47.40 billion, compared to the consensus revenue estimate of $48.59 billion.

10 brokers have issued 1 year price objectives for Merck & Co., Inc.'s shares. Their forecasts range from $76.79 to $101.00. On average, they expect Merck & Co., Inc.'s share price to reach $92.22 in the next year. This suggests a possible upside of 28.4% from the stock's current price.
View analysts' price targets for Merck & Co., Inc. or view top-rated stocks among Wall Street analysts.

1,343 employees have rated Merck & Co., Inc. CEO Kenneth C. Frazier on Glassdoor.com. Kenneth C. Frazier has an approval rating of 94% among Merck & Co., Inc.'s employees. This puts Kenneth C. Frazier in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Merck & Co., Inc. include Johnson & Johnson (JNJ), Pfizer (PFE), Eli Lilly and (LLY), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Horizon Therapeutics Public (HZNP), Royalty Pharma (RPRX), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Nektar Therapeutics (NKTR), Pacira BioSciences (PCRX), Corcept Therapeutics (CORT), Supernus Pharmaceuticals (SUPN) and Omeros (OMER).
View all of MRK's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Merck & Co., Inc. investors own include Pfizer (PFE), Johnson & Johnson (JNJ), AT&T (T), Intel (INTC), Cisco Systems (CSCO), The Walt Disney (DIS), Verizon Communications (VZ), JPMorgan Chase & Co. (JPM), AbbVie (ABBV) and The Home Depot (HD).

Merck & Co., Inc. trades on the New York Stock Exchange (NYSE) under the ticker symbol "MRK."

Merck & Co., Inc.'s stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (8.91%), BlackRock Inc. (7.39%), State Street Corp (4.51%), Geode Capital Management LLC (1.75%), Franklin Resources Inc. (1.53%) and Bank of America Corp DE (1.39%). Company insiders that own Merck & Co., Inc. stock include Frank Clyburn, Julie L Gerberding, Robert M Davis, Sanat Chattopadhyay and Wendell P Weeks.
View institutional ownership trends for Merck & Co., Inc..

MRK stock was sold by a variety of institutional investors in the last quarter, including Berkshire Hathaway Inc, BlackRock Inc., Nuveen Asset Management LLC, Capital International Investors, Price T Rowe Associates Inc. MD, Prudential Financial Inc., Bank of America Corp DE, and Bank of America Corp DE. Company insiders that have sold Merck & Co., Inc. company stock in the last year include Frank Clyburn, and Robert M Davis.
View insider buying and selling activity for Merck & Co., Inc. or view top insider-selling stocks.

MRK stock was acquired by a variety of institutional investors in the last quarter, including Amundi, Barrow Hanley Mewhinney & Strauss LLC, LSV Asset Management, FMR LLC, Morgan Stanley, Charles Schwab Investment Management Inc., Franklin Resources Inc., and Invesco Ltd..
View insider buying and selling activity for Merck & Co., Inc. or or view top insider-buying stocks.

Shares of MRK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MRK stock can currently be purchased for approximately $71.81.

Merck & Co., Inc. has a market capitalization of $181.78 billion and generates $47.99 billion in revenue each year. The company earns $7.07 billion in net income (profit) each year or $5.94 on an earnings per share basis.

Merck & Co., Inc. employs 74,000 workers across the globe.

Merck & Co., Inc. was founded in 1891.

The official website for Merck & Co., Inc. is www.merck.com.

Merck & Co., Inc. is headquartered at 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033.

Merck & Co., Inc.'s mailing address is 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033. The company can be reached via phone at (908) 740-4000 or via email at [email protected]